Skip to main content

Funding Opportunities

Thank you for your important research toward breakthroughs for people with Parkinson's and for your interest in working with The Michael J. Fox Foundation.

Below are MJFF’s open funding programs.

More information on our Application Guidelines can be found here, while information on proposal budgets and team composition can be found here in English and here in LATAM Spanish

Email grants@michaeljfox.org with questions.

Browse Funding Opportunities

Open Programs

  • Personalized Approaches for Understanding, Assessing and Improving Gait in Parkinson’s Disease Research Program
    Objective:
    This program seeks to fund clinical testing on personalized approaches for understanding, assessing and improving gait in Parkinson’s disease (PD) to address the wide variances of gait challenges across the continuum of the disease. The program aims to establish standardized assessment and tailor treatments to individual symptoms that improves gait and motor-cognitive functions.
  • Parkinson's Disease Therapeutics Pipeline Program
    Objective:
    This program seeks to advance therapeutic development through pre-clinical and/or clinical testing of approaches addressing unmet needs of people with Parkinson’s disease (PD). The program is set up to benefit therapeutics with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms.
  • The Edmond J. Safra Fellowship in Movement Disorders
    Aluminum seal commemorating anniversary
    Objective:
    The Edmond J. Safra Fellowship in Movement Disorders aims to grow the global base of movement disorder specialists — neurologists with additional training in Parkinson's disease and other movement disorders — by training movement disorder clinician-researchers who can provide expert care and lead scientific advances.

Closed Programs

  • Black and African American Connections to Parkinson's Disease (BLAAC PD)
    GP2 Logo
    Objective:
    This program seeks to expand understanding of Parkinson’s disease within the Black and African American community and contribute to a more holistic, global understanding of the disease.
  • Freezing of Gait (FOG) in Parkinson’s Disease Research Program
    Objective:
    This program supports clinical studies that advance the knowledge of Freezing of Gait (FOG) and balance disorders to support therapeutic treatments. Applications are open to multi-centric studies with cross-disciplinary teams.
  • Alpha-synuclein Post-translational Modification Quantification Program
    Objective:
    This program seeks to establish robust methods and tools that can quantify the amount and regional distribution of post-translational modifications of alpha-synuclein in Parkinson’s disease-relevant brain regions.
  • Lysosomal Biomarkers Program
    Objective:
    This program seeks to develop, optimize and validate biomarkers related to lysosomal function, protein clearance and lipid homeostasis.
  • Circuits & Cellular Targets for Parkinson’s Symptoms – Pre-clinical Program
    Objective:
    This program seeks to further our understanding of the pathophysiological mechanisms that contribute to Parkinson’s disease with pre-clinical models. It also aims to identify the specific links between brain regions, cell types and signaling pathways to behavioral endpoints related to motor and non-motor symptoms of Parkinson’s disease (PD).
  • Data-Driven Subtyping & Stratification Program
    Objective:
    This program supports efforts to identify and validate Parkinson’s disease (PD) subtypes using existing data. Outcomes should be leveraged toward improving biomarkers, therapeutic/clinical trial strategies and precision medicine.
  • Therapeutic Pipeline Program
    Objective:
    The Michael J. Fox Foundation funds work with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care.
  • Target Advancement Program
    Objective:
    The Michael J. Fox Foundation funds work that leverages and translates basic research to enable therapeutic development.
  • Translational Pipeline Program
    Objective:
    This program will support target validation, pre-clinical and clinical work to foster and accelerate the development of Parkinson’s therapeutics with potential for fundamentally altering disease course or significantly improving management of symptoms.
  • Development and Validation of Improved Outcome Measures
    Objective:
    This program funds work to develop objective biomarkers that can support therapeutic development in Parkinson’s.
  • Biomarkers to Support Therapeutic Trials Program
    Objective:
    This program supports biomarkers research that will develop, optimize or analytically validate new or existing outcome measures to directly inform and transform therapeutic development.  
  • Analysis of Patient-Reported Outcomes from Fox Insight
    Objective:
    This program funds analyses of the patient-reported outcomes (PROs) and genetic data collected through the Fox Insight study.
  • Novel PET Tracer Development Program
    Objective:
    This program supports work to develop and validate PET imaging techniques utilizing radiotracers of a variety of disease-relevant targets that can ultimately be implemented in clinical practice and clinical trials. 
  • PIPETTE: 4R Tau and Alpha-Synuclein PET Tracer Development
    Objective:
    The PIPETTE Consortium (Philanthropic Investments in PET TracErs) is a funding partnership formed in 2017 by The Michael J. Fox Foundation and Rainwater Charitable Foundation (conveners of the Tau Consortium).
  • ASAP Collaborative Research Network: Circuitry and Brain-body Interactions
    ASAP logo
    Objective:
    The ASAP Collaborative Research Network, a program of the Aligning Science Across Parkinson’s (ASAP) initiative being implemented through The Michael J. Fox Foundation, seeks to support multidisciplinary, multi-institutional research teams to address key knowledge gaps in the basic mechanisms that contribute to Parkinson’s development and progression.
  • Investigating Environmental Factors that Increase the Risk for Parkinson’s Disease
    Objective:
    This funding program supported projects to investigate environmental exposures, such as chemicals or toxic emissions, that increase the risk of PD and/or influence disease progression.
  • Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research
    Objective:
    The Michael J. Fox Foundation seeks applications with the potential to increase knowledge about Parkinson’s disease in populations that have been excluded from or underrepresented in research.
  • Alpha-synuclein Seed Amplification Assay Program
    Objective:
    This program supports research that will facilitate integration of alpha-synuclein seed amplification assays into clinical studies for the purposes of predicting prognosis, tracking disease progression and monitoring therapeutic response.
  • Therapeutic Pipeline Program: Pre-clinical Studies
    Objective:
    This funding program — an Edmond J. Safra Core Program for PD Research — will support development of Parkinson’s disease (PD) therapeutics with potential for fundamentally altering disease course or significantly improving non-motor or motor symptoms.
  • Parkinson’s Pathway Biomarkers
    Objective:
    The Michael J. Fox Foundation seeks applications with the potential to develop new/better biomarkers for measuring pathway function or dysfunction that can support therapeutic development for affected pathways in Parkinson’s disease (PD).
  • Target Advancement: Tool Generation and Target Validation
    Objective:
    This funding program — an Edmond J. Safra Core Program for PD Research — seeks to build conclusive evidence and develop field-enabling tools around early-stage biological targets in Parkinson’s disease (PD).
  • Cellular Phenotyping in Human iPSCs
    Objective:
    This program will support phenotyping of human induced pluripotent stem cells (iPSCs) from our Parkinson’s Progression Markers Initiative (PPMI). Such work will facilitate future mechanistic studies and expedite drug screening and proof-of-concept testing for Parkinson’s therapeutics.
  • Ken Griffin Alpha-synuclein Imaging Competition
    Ken Griffin Alpha-synuclein Imaging Competition Logo
    Objective:
    The Michael J. Fox Foundation has prioritized alpha-synuclein imaging as the most likely imaging approach to have an impact for therapeutic development. The goal of this $10-million funding program is to deliver a selective alpha-synuclein PET tracer for use in clinical studies.
  • Parkinson’s Pathway Molecular Data Analysis
    Objective:
    This funding program will support high-impact projects that utilize existing data resources to increase molecular understanding of Parkinson’s disease (PD), correlate biological changes to clinical/other outcomes, and more deeply interrogate disrupted pathways in PD.
  • MRI Biomarkers: Data Analysis and Tool Generation
    Objective:
    This funding program will support studies to develop reproducible diagnostic, prognostic, and monitoring magnetic resonance imaging (MRI) biomarkers.
  • Illustrated avatar with check mark.

    Grant Portal

    View submitted or in progress applications.

  • Illustrated envelope containing alert message.

    Funding Alerts

    Sign up for email updates on resources and initiatives to accelerate research and improve Parkinson's care.

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.